Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

EMD 121974 in Treating Patients With Advanced Solid Tumors

This study has been completed.
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: August 10, 2001
Last updated: January 24, 2013
Last verified: January 2013
Phase I trial to study the effectiveness of EMD 121974 in treating patients who have advanced solid tumors. EMD 121974 may slow the growth of solid tumors by stopping blood flow to the tumor

Condition Intervention Phase
Unspecified Adult Solid Tumor, Protocol Specific
Drug: cilengitide
Other: pharmacological study
Other: laboratory biomarker analysis
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Study of EMD 121974 in Patients With Advanced Solid Tumors

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • MTD of cilengitide defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. [ Time Frame: 4 weeks ]
    Graded according to the NCI Common Toxicity Criteria version 2.0.

  • Toxic effects of cilengitide described as an adverse event that has an attribution of possibly, probably or definitely related to investigational treatment [ Time Frame: Up to 4 years ]
    Graded according to the NCI Common Toxicity Criteria version 2.0.

  • Biological activity of this regimen [ Time Frame: Up to 4 years ]
    Measured buy TUNEL assay, CD31 immunohistochemistry, dynamic contrast-enhanced MRI, and FDG-PET scan.

Secondary Outcome Measures:
  • Pharmacokinetics of cilengitide [ Time Frame: At 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 8.0, and 24.0 hours post-end-of-infusion on day 1 of course 1 ]
  • Observation of response consisting of complete response, partial response, or stable disease, evaluated using the RECIST criteria [ Time Frame: Up to 4 years ]
  • Time to progression [ Time Frame: Up to 4 years ]

Enrollment: 35
Study Start Date: May 2001
Primary Completion Date: May 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment (cilengitide)
Patients receive EMD 121974 IV over 1 hour twice weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Drug: cilengitide
Given IV
Other Name: EMD 121974
Other: pharmacological study
Correlative studies
Other Name: pharmacological studies
Other: laboratory biomarker analysis
Correlative studies

Detailed Description:


I. Determine the toxic effects and maximum tolerated dose of EMD 121974 in patients with advanced solid tumors.

II. Determine the biologic activity of this drug in these patients. III. Determine the pharmacokinetic profile and plasma biological effects of this drug and identify any relationship with its biologic activity or observed toxicity in these patients.

IV. Determine, preliminarily, the antitumor efficacy of this drug in these patients.

OUTLINE: This is a dose-escalation study.

Patients receive EMD 121974 IV over 1 hour twice weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-10 patients receive escalating doses of EMD 121974 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed solid tumor that is refractory to standard therapy or for which no standard therapy exists
  • Tumors must be amenable to minimally-invasive biopsy (i.e., tumors must be superficial enough to be sampled by punch biopsy or core biopsy procedure without radiologic guidance)*
  • No uncontrolled brain metastases, including symptomatic lesions or lesions requiring glucocorticoids and/or anticonvulsants to suppress symptoms

    • Negative brain scan required if there are signs and symptoms suggestive of brain metastasis
  • Performance status - ECOG 0-2
  • Performance status - Karnofsky 60-100%
  • At least 12 weeks
  • WBC at least 3,000/mm^3
  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3
  • Hemoglobin at least 9 g/dL
  • Bilirubin normal
  • AST and ALT no greater than 2.5 times upper limit of normal
  • Creatinine normal
  • Creatinine clearance at least 60 mL/min
  • No symptomatic congestive heart failure
  • No unstable angina pectoris
  • No ongoing or active infection
  • No other concurrent serious systemic disorders (e.g., significant CNS illness) that would preclude study
  • No concurrent psychiatric illness or social situations that would preclude study
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No other concurrent anticancer immunotherapy
  • Concurrent hematologic growth factors for cytopenias allowed
  • At least 4 weeks since prior anticancer chemotherapy (6 weeks for nitrosoureas, carmustine, or mitomycin) and recovered
  • See Disease Characteristics
  • No concurrent anticancer hormonal therapy
  • Concurrent oral contraceptives or postmenopausal hormone replacement allowed
  • Recovered from prior radiotherapy
  • At least 2 weeks since prior palliative radiotherapy to bone or brain metastases
  • At least 4 weeks since prior anticancer radiotherapy
  • No concurrent anticancer radiotherapy
  • Not specified
  • At least 4 weeks since prior anticancer therapy and recovered
  • At least 4 weeks since prior investigational agents
  • Any number of prior therapies allowed
  • No other concurrent anticancer investigational or commercial agents
  • No concurrent combination antiretroviral therapy for HIV-positive patients
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00022113

United States, Colorado
University of Colorado
Denver, Colorado, United States, 80217-3364
Sponsors and Collaborators
National Cancer Institute (NCI)
Principal Investigator: Michele Basche University of Colorado, Denver
  More Information

Responsible Party: National Cancer Institute (NCI) Identifier: NCT00022113     History of Changes
Other Study ID Numbers: NCI-2012-02392
U01CA099176 ( US NIH Grant/Contract Award Number )
CDR0000068786 ( Registry Identifier: PDQ (Physician Data Query) )
Study First Received: August 10, 2001
Last Updated: January 24, 2013 processed this record on May 24, 2017